| NCT ID | NCT07053891 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Otsuka Pharmaceutical Co., Ltd. |
| Condition | Lupus Nephritis |
| Study Type | OBSERVATIONAL |
| Enrollment | 400 participants |
| Start Date | 2025-09-17 |
| Primary Completion | 2031-06-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 400 participants in total. It began in 2025-09-17 with a primary completion date of 2031-06-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this study is to survey the safety of LUPKYNIS in patients with lupus nephritis under actual use conditions. In addition, information on efficacy will be collected.
Eligibility Criteria
Inclusion Criteria: * Patients who are newly starting administration of LUPKYNIS for lupus nephritis Exclusion Criteria: \-
Contact & Investigator
Pharmacovigilance Department Otsuka Pharmaceutical Co., Ltd
✉ komaniwa.satoshi@otsuka.jp📞 +81-6-6943-7722
Frequently Asked Questions
Who can join the NCT07053891 clinical trial?
This trial is open to participants of all sexes, aged 15 Years or older, studying Lupus Nephritis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07053891 currently recruiting?
Yes, NCT07053891 is actively recruiting participants. Contact the research team at komaniwa.satoshi@otsuka.jp for enrollment information.
Where is the NCT07053891 trial being conducted?
This trial is being conducted at Osaka, Japan.
Who is sponsoring the NCT07053891 clinical trial?
NCT07053891 is sponsored by Otsuka Pharmaceutical Co., Ltd.. The trial plans to enroll 400 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.